Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14437980 | 0.74 | — | — | |
| SCHEMBL13486512 | 0.71 | HTR3A (0.36) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL22693060 | 0.70 | NOS3 (0.35) | — | |
| SCHEMBL20631781 | 0.69 | — | — | |
| SCHEMBL20631795 | 0.69 | LMNA (0.38) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL19337377 | 0.69 | PARP1 (0.30) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL13612342 | 0.68 | PSMB5 (0.36) | MEN1KMT2A | |
| SCHEMBL21959622 | 0.68 | NOS3 (0.32) | — | |
| SCHEMBL18238951 | 0.65 | MEN1 (0.37) | MEN1ALDH1A1GAAKMT2A | |
| SCHEMBL17265838 | 0.65 | DYRK1A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | MEN1 3396/4885ALDH1A1 3098/4885GAA 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.